Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer

Vincenzo Di Nunno, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Michelangelo Fiorentino, Chiara Ciccarese, Roberto Iacovelli, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Rodolfo Montironi

Research output: Contribution to journalComment/debate

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)2559-2564
Number of pages6
JournalFuture Oncology
Volume14
Issue number25
DOIs
StatePublished - Oct 2018

Keywords

  • MET inhibitor
  • angiogenesis
  • bone metastasis
  • cabozantinib
  • castration-resistant prostate cancer
  • metastatic RCC
  • multityrosine kinases inhibitor
  • osteoblastic activation
  • renal cell carcinoma
  • target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Di Nunno, V., Cimadamore, A., Santoni, M., Scarpelli, M., Fiorentino, M., Ciccarese, C., Iacovelli, R., Cheng, L., Lopez-Beltran, A., Massari, F., & Montironi, R. (2018). Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology, 14(25), 2559-2564. https://doi.org/10.2217/fon-2018-0158